Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study
Journal for ImmunoTherapy of Cancer · 2026-05 · 14 (5) · e014641
DOI: 10.1136/jitc-2025-014641 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 28.05.2026. Verfasst von Alice Tison und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, CHU de Brest, LBAI UMR1227, Univ Brest, Inserm, Brest, France alice.tison@chu-brest.fr. Hauptthemen laut MEDLINE: Polymyalgia Rheumatica, Immune Checkpoint Inhibitors, Arthritis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Philippe Foundation, the French network of University Hospitals HUGO, the Brest University Hospital endowment fund.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitor (ICI)-related inflammatory arthritis occurs in approximately 6% of ICI-treated patients, and is often long-lasting. The clinical presentation is heterogeneous, and often loosely resembles either rheumatoid arthritis (ICI-IA) with peripheral presentation, or polymyalgia rheumatica (ICI-PMR) with predominant bilateral shoulder and hip pain and stiffness. Our objective was to compare clinical features, immunosuppressive treatment, and cancer outcomes between ICI-IA and ICI-PMR.
Methods
Data were extracted from the Rheumatology Adverse Events Due to Immunotherapy Observational Study multicenter prospective registry, regarding patients with rheumatologist-diagnosed ICI-IA or ICI-PMR and no preexisting primary IA/PMR. Clinical features were collected at the first visit in the registry. Multivariable logistic regression was used to compare second-line immunosuppressive drug utilization between groups. Kaplan-Meier curves were constructed to compare time of prednisone tapering to a dose of (1) 10 mg and (2) 5 mg from the baseline registry visit. Cox proportional hazard models were used to compare progression-free survival (PFS). Date of first cancer progression from arthritis onset was extracted based on documentation of imaging and/or pathology in the medical record. Patients with ICI-PMR were also compared with an independent cohort of patients with primary PMR.
Results
We analyzed 490 patients: 418 with ICI-IA and 72 with ICI-PMR. Compared with patients with ICI-IA, patients with ICI-PMR were older (70 vs 63 years old, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, CHU de Brest, LBAI UMR1227, Univ Brest, Inserm, Brest, France alice.tison@chu-brest.fr.
- Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA.
- Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
- Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA.
- Department of Health Services Research and Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Cancer Sciences, Global Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic Foundation, Cleveland, Ohio, USA. Cancer Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE.
Förderung
- Philippe Foundation
- the French network of University Hospitals HUGO
- the Brest University Hospital endowment fund
- National Institutes of Health/National Institute of Allergy and Infectious Diseases
- The French Society of Rheumatology
- NIH/NIAMS
- the Camille Julia Morgan Arthritis Research and Education Fund
Zitieren
APA
Tison, A., Jannat-Khah, D., Cappelli, L. C., Suarez-Almazor, M. E., Abdel-Wahab, N., Reid, P., Sparks, J. A., Braaten, T. J., Meara, A., Calabrese, C., Katsumoto, T., Ghosh, N., Ge, K., Saraux, A., Devauchelle-Pensec, V., Shah, A. A., Bingham, C. O., & Bass, A. R. (2026). Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study. Journal for ImmunoTherapy of Cancer, 14(5), e014641. https://doi.org/10.1136/jitc-2025-014641
Vancouver
Tison A, Jannat-Khah D, Cappelli LC, Suarez-Almazor ME, Abdel-Wahab N, Reid P, et al. Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study. Journal for ImmunoTherapy of Cancer. 2026;14(5):e014641. doi:10.1136/jitc-2025-014641
BibTeX
@article{Tison2026,
author = {Tison, Alice and Jannat-Khah, Deanna and Cappelli, Laura C and Suarez-Almazor, Maria E and Abdel-Wahab, Noha and Reid, Pankti and Sparks, Jeffrey A and Braaten, Tawnie J and Meara, Alexa and Calabrese, Cassandra and Katsumoto, Tamiko and Ghosh, Nilasha and Ge, Kyle and Saraux, Alain and Devauchelle-Pensec, Valérie and Shah, Ami A and Bingham, Clifton O and Bass, Anne R},
title = {Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {5},
pages = {e014641},
doi = {10.1136/jitc-2025-014641}
}
EUVIMED